Beijing, December 29, 2023 — The R&D-based Pharmaceutical Association Committee (RDPAC) is pleased to announce key changes within its Executive Committee for the term 2024-2025. Pavol Dobrocky, President and CEO of Boehringer Ingelheim Greater China, will be assuming a new leadership position within Boehringer Ingelheim in Europe; therefore, he will no longer be able to serve at RDPAC Executive Committee. Cecilia Qi, Vice President of GSK and General Manager of GSK China, will join RDPAC Executive Committee and serve a tenure of two years between 2024-2025 as of January 1st, 2024.
Cecilia Qi
Member of RDPAC 2024-2025 Executive Committee
Vice President of GSK and General Manager of GSK China
Cecilia Qi expressed, “I am deeply honored to serve as part of the RDPAC 2024-2025 Executive Committee. Throughout my tenure, I eagerly anticipate collaborating closely with fellow EC members, member companies, and all stakeholders to contribute to the robust and sustainable development of China’s biopharmaceutical industry. My goal is to bring innovative medicines to more Chinese patients and support the realization of the ‘Healthy China’ Initiative. Additionally, I will continue to fulfill my responsibilities in Ethical Business Practice as the EC sponsor for RDPAC’s Ethics and Compliance working group, actively contributing to the cultivation of a healthy industry ecosystem.”
Recognizing Pavol Dobrocky's dedicated leadership, particularly in spearheading the RDPAC IP working group, the Committee acknowledges his unwavering commitment and substantial contributions to RDPAC's advocacy efforts. The Committee expresses heartfelt gratitude to him and extends best wishes for continued success in all his future endeavors.
The newly elected RDPAC Executive Committee is well-positioned to continue guiding RDPAC in alignment with its mission and vision in China. This entails collaborative efforts with key stakeholders to foster international cooperation, bridge communication between the government and the industry, and advocate for sustainable policies that incentivize pharmaceutical innovation. The ultimate goal is to ensure that innovative medicines benefit Chinese patients as early and as extensively as possible. Simultaneously, RDPAC remains committed to elevating China's pharmaceutical innovation ecosystem, fostering higher-quality industry development, and contributing to the ‘Healthy China’ initiative, aiming to enhance the health and well-being of the people in China.
